Mar 07, 2011 18:26 ET
Stem Cell Therapeutics Corp. Announces Commencement of MS Research Program

CALGARY, ALBERTA--(Marketwire - March 7, 2011) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") is pleased to announce today that the Multiple Sclerosis (MS) phase II clinical trial is proceeding. This program will be executed by the University of Calgary utilizing funding from the Stem Cell Network, based in Ottawa. The financial commitment of SCT is limited to providing the drug (prolactin) for the program at a cost not expected to exceed $500,000. Access to funding makes this program extremely cost effective for the Company as the total clinical trial is expected to cost 4-5 times more than the cost of the drug.

This decision reflects SCT's ongoing commitment to execute its business plan to facilitate the value realization of its core programs. The Company continues to advance its other high priority programs, Stroke and Traumatic Brain Injury.